Clinical Trials Logo

Advanced Solid Cancer clinical trials

View clinical trials related to Advanced Solid Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05947474 Recruiting - Clinical trials for Advanced Solid Cancer

ORB-011 In Patients With Advanced Solid Tumors

ORB
Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.

NCT ID: NCT05770310 Recruiting - Clinical trials for Advanced Solid Cancer

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Start date: February 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of JS015 in patients with advanced solid tumors. The Recommended dose for phase II trial (RP2D) was determined based on the safety, pharmacokinetics, and initial efficacy data of the dose escalation and extension.

NCT ID: NCT04877717 Recruiting - Clinical trials for Advanced Solid Cancer

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with advanced solid cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904

NCT ID: NCT03917043 Recruiting - Ovarian Cancer Clinical Trials

APG-2449 in Patients With Advanced Solid Tumors

Start date: May 27, 2019
Phase: Phase 1
Study type: Interventional

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.

NCT ID: NCT03791112 Recruiting - Clinical trials for Advanced Solid Cancer

A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor

Start date: July 18, 2019
Phase: Phase 1
Study type: Interventional

This was an open-label Phase I study. The primary objective of the study was to assess safety, tolerability, efficacy, and pharmacokinetic characteristics of BPI-16350 in different dose groups.

NCT ID: NCT03618043 Recruiting - Clinical trials for Advanced Solid Cancer

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

Start date: September 13, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study of SH-1028 with dose escalation cohorts in locally advanced solid cancer patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent or standard treatment.